No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 11
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Actuate Therapeutics Inc (ACTU) stock was $0.87 as of Oct 5, 2026, 4:00 PM EDT, up 6.83% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -87.3%
Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers.
Biotechnology · Fort Worth, TX
Next Earnings Date
Nov 12, 2026
37 days away
EPS Estimate
-0.18
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.20
vs Estimate
$-0.20
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1ACTU | $20.93M | $0.87 | +6.83% | -87.34% | N/A | N/A | N/A |
| 2AYTU | $21.90M | $2.04 | -1.45% | -6.80% | -48.14% | -68.87% | vs ACTU |
| 3COSM | $18.82M | $0.35 | -9.03% | -67.82% | -68.41% | -45.52% | vs ACTU |
| 4ESLA | $18.77M | $0.44 | -5.98% | -66.24% | -46.34% | N/A | vs ACTU |
| 5ATOS | $24.44M | $2.45 | +4.70% | -83.69% | -44.50% | -39.47% | vs ACTU |
| 6KYNB | $24.65M | $6.09 | -3.49% | -47.92% | -52.67% | -35.88% | vs ACTU |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 3 analysts
Average Price Target
$11.68
+1235.4% upside
Low
$8.00
Current
$0.87
High
$15.05
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.20 | $-0.17 | $-0.14 | 2 |
| Quarter ending Dec 2026 | $-0.19 | $-0.17 | $-0.14 | 2 |
| Quarter ending Mar 2027 | $-0.17 | $-0.17 | $-0.17 | 1 |
| Quarter ending Jun 2027 | $-0.17 | $-0.17 | $-0.17 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.85 | $-0.73 | $-0.61 | 2 |
| FY 2027 | $-0.74 | $-0.66 | $-0.57 | 2 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $0.00 | $0.00 | $0.00 | 0 |
| FY 2027 | $6.24M | $6.24M | $6.24M | 2 |
